Linked Life Data

2647926

Source:http://linkedlifedata.com/resource/pubmed/id/2647926

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2647926rdf:typepubmed:Citationlld:pubmed
pubmed-article:2647926lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0003842lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0221464lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0042384lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0024518lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0522536lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:2647926lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:2647926pubmed:issue1lld:pubmed
pubmed-article:2647926pubmed:dateCreated1989-4-27lld:pubmed
pubmed-article:2647926pubmed:abstractTextRecently, a potentially lethal pattern of vascular rejection has been described in heart transplant patients treated with cyclosporine. The purpose of this study was to identify potential immune mechanisms responsible for the development of coronary vascular injury associated with acute rejection. Our hypothesis was that changes in histocompatibility (MHC) expression induced by immunosuppressive therapy with cyclosporine plays an important role in directing an immune response to the arterial bed. With the ACI to Lewis allograft model, we compared the histology and immunohistology of both unmodified allograft rejection at days 2, 3, and 4 after transplantation, and allograft rejection modified by pretreatment with cyclosporine. Both models exhibit histologic evidence of early rejection before extensive myocyte necrosis is seen. Unmodified early rejection develops rapidly and is associated with dense MHC class I antigen expression on both myocytes and venous endothelium. Cyclosporine-modified rejection develops more slowly and is characterized by an arterial vasculitis. This modified pattern of rejection is associated with increased myocardial expression of MHC class II antigens with the arterial bed preferentially expressing increased MHC antigens. It is interesting to speculate that in the setting of a slower developing rejection process, the preferential expression of MHC antigens within the arterial bed produces a delayed-type hypersensitivity response directed toward either the endothelium and/or adjacent MHC class II expressing myocytes. A prolonged periarterial and intraluminal inflammatory reaction may then produce a true vasculitis, which may be detrimental to the survival of the graft.lld:pubmed
pubmed-article:2647926pubmed:languageenglld:pubmed
pubmed-article:2647926pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2647926pubmed:citationSubsetIMlld:pubmed
pubmed-article:2647926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2647926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2647926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2647926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2647926pubmed:statusMEDLINElld:pubmed
pubmed-article:2647926pubmed:issn0887-2570lld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:SellK WKWlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:BeschornerW...lld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:RoseN RNRlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:TamuraFFlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:UedaKKlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:BaumgartnerW...lld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:HerskowitzAAlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:NeumannD ADAlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:SlepianMMlld:pubmed
pubmed-article:2647926pubmed:authorpubmed-author:ReitzB RBRlld:pubmed
pubmed-article:2647926pubmed:issnTypePrintlld:pubmed
pubmed-article:2647926pubmed:volume8lld:pubmed
pubmed-article:2647926pubmed:ownerNLMlld:pubmed
pubmed-article:2647926pubmed:authorsCompleteNlld:pubmed
pubmed-article:2647926pubmed:pagination11-9lld:pubmed
pubmed-article:2647926pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:meshHeadingpubmed-meshheading:2647926-...lld:pubmed
pubmed-article:2647926pubmed:articleTitleInduction of donor major histocompatibility complex antigens in coronary arterial vessels: mechanism of arterial vasculitis in rat allografts treated with cyclosporine.lld:pubmed
pubmed-article:2647926pubmed:affiliationDepartment of Immunology and Infectious Diseases, Johns Hopkins Medical Institutions, Baltimore, Maryland.lld:pubmed
pubmed-article:2647926pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2647926lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2647926lld:pubmed